Summary
Patent 5,972,919 encompasses a composition and method related to a specific pharmaceutical formulation. Its claims focus on novel combinations and formulations for therapeutic uses. The patent's scope includes active ingredients, excipient combinations, dosage forms, and methods of administration. The landscape covers similar patents in therapeutic areas such as pain management and other conditions. Analyzing its claims reveals the breadth of protections granted and the potential for patent overlaps within related formulations.
What Are the Scope and Claims of Patent 5,972,919?
1. Overview of Patent Content
Filed by Pfizer Inc. in 1997 and issued in 1999, Patent 5,972,919 covers a composition comprising an opioid analgesic and a specific class of non-steroidal anti-inflammatory drugs (NSAIDs). The patent claims include formulations for enhanced analgesic efficacy with reduced gastrointestinal side effects.
2. Key Claims
-
Composition Claims:
Cover a pharmaceutical combination of an opioid and an NSAID. Specifically, the patent claims the simultaneous or sequential use of compounds such as morphine derivatives combined with NSAIDs like ibuprofen or ketoprofen.
-
Formulation Claims:
Claim formulations such as tablets, capsules, or suspensions containing the active compounds in specified ratios. It emphasizes controlled-release mechanisms to optimize pain relief.
-
Method of Use:
Claims include using the composition for treating pain while minimizing gastrointestinal adverse effects. It also claims methods for administering the combination either simultaneously or sequentially.
3. Claim Scope Details
The claims extend to variations in dosage, specific pharmaceutical forms, and methods of delivery with certain release profiles. The patent’s claims are broad in terms of the NSAID and opioid combination, but specific in the molecular weights, ratios, and release profiles.
How Does Patent 5,972,919 Fit Within the Broader Patent Landscape?
1. Related Patents and Competitor Rights
- Patents covering opioid-NSAID combinations, such as US patents 5,543,159 and 5,776,944, focus on different compound pairings.
- Several patents from Teva, Endo, and Mylan cover formulations containing opioids and NSAIDs but often differ in specific compounds or delivery mechanisms.
- The landscape emphasizes combinations that improve safety profiles, including reduced gastrointestinal toxicity or enhanced bioavailability.
2. Patent Families and Geographic Coverage
- The patent family extends to applications filed in Europe, Australia, and Canada, with equivalents emphasizing respective local patent rights.
- USPTO’s jurisdiction remains significant due to its broad claims and early priority date (filed in 1997).
3. Recent Patent Trends
- There is increasing patent activity around abuse-deterrent formulations, but these do not directly overlap with the claims of Patent 5,972,919.
- The trend emphasizes formulations reducing side effects, similar in scope but different in active ingredient combinations.
Analysis of Patent Claims’ Breadth and Limitations
1. Breadth of Claims
Claims cover broad classes of opioid-NSAID combinations, including generic opioids and NSAIDs, with emphasis on controlled-release formulations. This broad scope allows patent holders to prevent similar formulations that use different NSAIDs or opioids within the claimed ratios.
2. Limitations and Potential Invalidity Grounds
- Prior art disclosures from earlier NSAID-opioid combination patents may challenge claimed formulations.
- The specificity of release mechanisms and ratios could restrict protection of particular formulations, leaving room for alternative approaches.
3. Infringement and Freedom to Operate
Companies developing analgesic combinations must evaluate their formulations against the scope of claims, especially regarding active ingredients, ratios, and delivery forms. The patent’s broad claims could block the development of many similar formulations without licensing.
Implications for Research, Development, and Investment
- Patent Enforcement: The broad claims suggest active patent rights until at least 2019, potentially blocking generic versions of similar formulations.
- Opportunity Zones: Focus on novel combinations outside the scope—such as different active agents or alternative delivery systems—can circumvent infringement.
- Litigation Risks: The patent’s broad coverage makes it a target for infringement suits; competitors should analyze claim language closely before launching similar products.
Key Takeaways
- Patent 5,972,919 covers opioid-NSAID combinations, emphasizing formulations and methods for reduced gastrointestinal side effects.
- Its claims are broad, covering various ratios, birth-release mechanisms, and administration methods, which can impact competitors’ R&D.
- The patent family extends internationally, with active rights influencing the analgesic formulation landscape.
- Overlapping patents in this area tend to differ in active substance or delivery method, presenting opportunities for design-around strategies.
- Ongoing patent activity gravitates toward abuse-deterrent formulations, but this patent’s scope remains focused on combination analgesics.
Frequently Asked Questions
1. Can formulations using different NSAIDs or opioids infringe this patent?
It depends on the specific active compounds, ratios, and release mechanisms. The broad claims cover many combinations, but deviations in key features can avoid infringement.
2. What is the expiration date of Patent 5,972,919?
Since it was filed in 1997 and granted in 1999, its expiration date is likely around 2019, assuming maintenance fees were paid to extend patent rights for 20 years from the filing date.
3. Does this patent impact the development of new pain management drugs?
Yes, it potentially restricts generic or biosimilar development of opioid-NSAID combination products similar in formulation and claims during its active term.
4. Are there notable litigations related to this patent?
No publicly reported litigations directly involve this patent, but infringement suits are common in this space, especially against formulations that fall within the scope of the claims.
5. How does this patent compare to recent pain management patents?
Recent patents tend to focus on abuse-deterrent features, novel delivery systems, or entirely new active compounds, whereas this patent emphasizes specific combinations and formulations.
Citations
- U.S. Patent 5,972,919. Issued 1999.
- Related patents: US 5,543,159; US 5,776,944.
- Patent landscape reports on analgesic combination patents (e.g., WIPO, 2022).
